SELLAS Life Sciences hits 80th event in AML phase 3 trial
Tweet Send to a Friend
SELLAS Life Sciences Group (NASDAQ: SLS) announced that its pivotal Phase 3 REGAL trial evaluating galinpepimut-S (GPS) in patients with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




